Bristol-Myers Squibb (BMY) Q4 2024 Annual Earnings
Bristol-Myers Squibb reported Q4 2024 revenue of $12.3B, beat analyst consensus of $11.6B by $774.6M. Diluted EPS came in at $1.67, beat the $1.47 consensus by $0.20. Bristol-Myers Squibb reports across 1 business segment, led by Biopharmaceuticals.
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Bristol-Myers Squibb's Q4 2024 earnings report.
Bristol-Myers Squibb (BMY) reported Q4 2024 earnings on February 6, 2025 before market open.
Bristol-Myers Squibb reported revenue of $12.3B and diluted EPS of $1.67 for Q4 2024.
Revenue beat the consensus estimate of $11.6B by $774.6M. EPS beat the consensus estimate of $1.47 by $0.20.
You can read the 10-K periodic report (0000014272-25-000039) directly on SEC EDGAR. The filing index links above go to sec.gov.